Related Experiment Video
Updated: Apr 15, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase
Tzung-Ju Wu1, Xiaowen Wang1, Yanjie Zhang2
1Rutgers Cancer Institute of New Jersey and Division of Cancer Pharmacology, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08903, USA; The Graduate Program in Cellular and Molecular Pharmacology, Rutgers University, Piscataway, NJ 08854, USA.
Abstract:
Protein kinases are therapeutic targets for human cancer. However, "gatekeeper" mutations in tyrosine kinases cause acquired clinical resistance, limiting long-term treatment benefits. mTOR is a key cancer driver and drug target. Numerous small-molecule mTOR kinase inhibitors have been developed, with some already in human clinical trials. Given our clinical experience with targeted therapeutics, acquired drug resistance in mTOR is thought likely, but not yet documented. Herein, we describe identification of a hot spot (L2185) for drug-resistant mutations, which is distinct from the gatekeeper site, and a chemical scaffold refractory to drug-resistant mutations. We also provide new insights into mTOR kinase structure and function. The hot spot mutations are potentially useful as surrogate biomarkers for acquired drug resistance in ongoing clinical trials and future treatments and for the design of the next generation of mTOR-targeted drugs. Our study provides a foundation for further research into mTOR kinase function and targeting.
Insights
Researchers identified a new mutation hotspot (L2185) in mTOR kinase, distinct from the gatekeeper site, which can cause drug resistance. This discovery aids in developing next-generation mTOR inhibitors and biomarkers for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Protein kinases, including mTOR, are crucial targets in cancer therapy.
- Acquired resistance to targeted therapies, often due to gatekeeper mutations, limits treatment efficacy.
- While resistance to mTOR inhibitors is anticipated, it remains largely undocumented.
Purpose of the Study:
- To identify novel sites of drug resistance mutations in mTOR kinase.
- To discover chemical scaffolds that overcome drug resistance.
- To provide insights into mTOR kinase structure and function for improved drug design.
Main Methods:
- Identification of mutation hotspots through resistance profiling.
- Structural analysis of mTOR kinase.
- Development and testing of novel chemical scaffolds against resistant mutations.
Main Results:
- A novel drug-resistant mutation hotspot (L2185) was identified in mTOR, separate from the gatekeeper site.
- A chemical scaffold demonstrating refractoriness to known drug-resistant mutations was developed.
- New structural and functional insights into mTOR kinase were elucidated.
Conclusions:
- The L2185 hotspot mutations can serve as biomarkers for acquired resistance in mTOR-targeted cancer therapies.
- The identified scaffold offers a promising strategy for next-generation mTOR inhibitors.
- This research lays the groundwork for advancing mTOR kinase targeting in cancer treatment.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
01:22PI3K/mTOR/AKT Signaling Pathway